Members News

28.06.2013Sustainable Growth of Protagen Protein Services GmbH
Protagen Protein Services GmbH (PPS) a leading service provider in Biosimilar analytics is acquired by Zukunftsfond Heilbronn, a major German Venture Capital provider, today.

We are supporting protein therapeutics development with our GMP certified analytical services for more than 15 years. In recent years we became a renowned expert in Biosimilar analytics and are currently supporting Biosimilar developments for more than 20 international sponsors including Generic, Big Pharma and Biotech Companies. The Protein Services Unit of Protagen AG was spun off as PPS in 2012 and was acquired by Zukunftsfond Heilbronn today.

We are delighted about the commitment of our new and strong investor. This will facilitate our continuous growth and enable us to increase our service portfolio further. Through this we can support the dynamic uptake in Biosimilar developments of our sponsors even better.

The Zukunftsfond Heilbronn is also the major investor in Panatecs GmbH having a complementary service portfolio in protein analysis including peptide synthesis. We are glad to join forces of Panatecs and Protagen Protein Services and provide added value to our customers.

Martin Blüggel, founder of Protagen will take over CEO position from Stefan Müllner, who will remain CEO of Protagen AG. Management will be complemented by Dr. Thomas Frischmuth, CEO of Panatecs, and newly appointed CFO of PPS.

We are looking forward to sustainable growth.

We are pleased to see a major milestone in Biosimilar history in coincidence: Celltrion announced EU market approval of a Biosimilar to Infliximab a few hours ago.